< Back to previous page
Project
Bringing a prophylactic Ebola vaccine to licensure (EBOVAC3).
The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease.
Date:1 Jun 2018 → 30 Sep 2024
Keywords:VACCINES, EBOLA
Disciplines:Vaccinology
Project type:Collaboration project
SDG-label by Aurora
Researchers
- Pierre Van Damme (Promoter)
Vaccine & Infectious Disease Institute (VAXINFECTIO)
Duration: 1 Jun 2018 → 30 Sep 2024 - Pierre Van Damme (Promoter)
Centre for the Evaluation of Vaccination (CEV)
Duration: 1 Jun 2018 → 30 Sep 2024 - Jean-Pierre Van geertruyden (Co-promoter)Duration: 1 Jan 2019 → 30 Sep 2024
- Hilde Revets (Co-promoter)
Vaccine & Infectious Disease Institute (VAXINFECTIO)
Duration: 1 Jun 2018 → 2 Jun 2019 - Jean-Pierre Van geertruyden (Co-promoter)
Epidemiology and social medicine (ESOC)
Duration: 1 Jun 2018 → 31 Dec 2018
Project partners
- Vaccine & Infectious Disease Institute (VAXINFECTIO) (Research group)
Project owner
From1 Jun 2018 → 31 Dec 2018 - London School of Hygiene & Tropical Medicine
Project Partner
From1 Jun 2018 → 30 Sep 2024 - Institut National de la santé et de la recherche médicale (INSERM)
Project Partner
From1 Jun 2018 → 30 Sep 2024 - Epidemiology and social medicine (ESOC) (Research group)From1 Jun 2018 → 31 Dec 2018
- Centre for the Evaluation of Vaccination (CEV) (Research group)
Project owner
From1 Jan 2019 → 30 Sep 2024 - Global Health Institute (GHI) (Research group)From1 Jan 2019 → 30 Sep 2024
Funding
1 - 1 of 1 results
- Funding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing(Principal funding)
Funding party: European Commission
Policy level funding: European
Publications
1 - 10 of 17
- Regulator experiences of trials during Ebola epidemics in Sierra Leone, Guinea, and the Democratic Republic of the Congo(2025)Published in: Tropical medicine and international healthISSN: 1360-2276Volume: 30Pages: 539 - 546
- Long-term experiences of health care providers using iris scanning as an identification tool in a vaccine trial in the Democratic Republic of the Congo: qualitative study(2025)Published in: JMIR Formative ResearchISSN: 2561-326XVolume: 9Pages: 1 - 12
- Researchers’ responsibilities in resource-constrained settings: experiences of implementing an ancillary care policy in a vaccine trial in the Democratic Republic of the Congo(2024)Published in: Research EthicsISSN: 1747-0161Volume: 20Pages: 79 - 95
- Within-host modeling to measure dynamics of antibody responses after natural infection or vaccination: a systematic review(2023)Published in: VaccineISSN: 0264-410XVolume: 41Pages: 3701 - 3709
- Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo(2025)Published in: VaccineISSN: 0264-410XVolume: 64Pages: 1 - 10
- Use of iris scanning for biometric recognition of healthy adults participating in an Ebola vaccine trial in the Democratic Republic of the Congo: mixed methods study(2021)Published in: Journal of medical internet researchISSN: 1439-4456Volume: 23
- The exclusion of pregnant women from an Ebola vaccine trial in Boende, western DRC: perceptions of female participants who became pregnant and community members(2025)Published in: VaccineISSN: 0264-410XVolume: 55Pages: 1 - 8
- Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: challenges, mitigations, and lessons learned(2023)Published in: VaccineISSN: 0264-410XVolume: 41Pages: 7587 - 7597
- Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, p(2024)Published in: The lancet infectious diseasesISSN: 1473-3099Volume: 24Pages: 746 - 759
- Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study pr(2021)Published in: BMJ openISSN: 2044-6055Volume: 11